The Molecular Basis of Malignant Pleural Mesothelioma.

Asbestos / adverse effects Computational Biology / methods Epigenesis, Genetic Gene Expression High-Throughput Nucleotide Sequencing Humans Mesothelioma, Malignant / etiology Pleural Neoplasms / etiology Transcriptome
Epigenetic Gene expression Genetic Mesothelioma Molecular

Journal

Thoracic surgery clinics
ISSN: 1558-5069
Titre abrégé: Thorac Surg Clin
Pays: United States
ID NLM: 101198195

Informations de publication

Date de publication:
Nov 2020
Historique:
entrez: 5 10 2020
pubmed: 6 10 2020
medline: 9 2 2021
Statut: ppublish

Résumé

Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural lining associated with asbestos exposure in greater than 80% of cases. It is characterized by molecular heterogeneity both between patients and within individual tumors. Next-generation sequencing technology and novel computational techniques have resulted in a greater understanding of the epigenetic, genetic, and transcriptomic hallmarks of MPM. This article reviews these features and discusses the implications of advances in MPM molecular biology in clinical practice.

Identifiants

DOI: 10.1016/j.thorsurg.2020.08.005 PMID: 33012428 PMC: PMC7536355
pubmed: 33012428
pii: S1547-4127(20)30067-0
doi: 10.1016/j.thorsurg.2020.08.005
pmc: PMC7536355
mid: NIHMS1629490
pii:
doi:

Substances chimiques

Asbestos 1332-21-4

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-393

Subventions

Organisme : NCI NIH HHS
ID : R01 CA120528
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure The authors disclose no potential conflicts of interest. Dr. Bueno reports research grants and clinical trials support from MedGenome, Roche, Verastem, Genentech, Merck, Gritstone, Epizyme, Siemens, NIH, and DOD. In addition, Dr. Bueno has 4 patents through the BWH (no royalties to date) and Equity in a new start-up company, Navigation Sciences.

Références

Clin Cancer Res. 2017 Jun 15;23(12):3191-3202
pubmed: 28003305
J Thorac Oncol. 2016 Oct;11(10):1615-26
pubmed: 27282309
J Thorac Oncol. 2019 Jul;14(7):1172-1183
pubmed: 31125736
Cancer Chemother Pharmacol. 2019 Aug;84(2):241-253
pubmed: 31119375
Clin Cancer Res. 2005 Jun 15;11(12):4406-14
pubmed: 15958625
Nat Med. 2015 Nov;21(11):1344-9
pubmed: 26437366
J Transl Med. 2012 Aug 30;10:179
pubmed: 22935333
FEBS Lett. 2000 Sep 1;480(2-3):95-100
pubmed: 11034307
Am J Pathol. 2005 Jun;166(6):1827-40
pubmed: 15920167
Cancer Res. 2006 Mar 15;66(6):2970-9
pubmed: 16540645
Nat Rev Cancer. 2017 Jul 25;17(8):475-488
pubmed: 28740119
Genes Chromosomes Cancer. 2016 Oct;55(10):741-9
pubmed: 27223342
Nat Rev Cancer. 2013 Mar;13(3):153-9
pubmed: 23550303
Lancet Oncol. 2017 May;18(5):623-630
pubmed: 28291584
Mutat Res. 2012 Apr-Jun;750(2):132-140
pubmed: 22198210
Cancer Res. 2009 Jan 1;69(1):227-34
pubmed: 19118007
Cancer Biol Ther. 2016;17(3):328-35
pubmed: 26853494
Bioinformatics. 2010 Jun 15;26(12):i237-45
pubmed: 20529912
Ann Thorac Surg. 2017 Mar;103(3):962-966
pubmed: 27765170
J Thorac Oncol. 2020 Apr;15(4):655-660
pubmed: 31887429
J Toxicol Environ Health A. 2019;82(20):1088-1102
pubmed: 31755376
Cancer Res. 2010 Jul 15;70(14):5686-94
pubmed: 20587528
J Mol Diagn. 2017 Jan;19(1):65-71
pubmed: 27863259
Cytogenet Genome Res. 2007;119(1-2):46-52
pubmed: 18160781
J Natl Cancer Inst. 2003 Apr 16;95(8):598-605
pubmed: 12697852
Nat Commun. 2019 Mar 22;10(1):1333
pubmed: 30902996
Recent Results Cancer Res. 2011;189:57-78
pubmed: 21479896
Cancer. 2011 Nov 15;117(22):5234-44
pubmed: 21523763
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):285-90
pubmed: 24347639
J Thorac Oncol. 2018 Aug;13(8):1189-1203
pubmed: 29723687
Virchows Arch. 2008 Dec;453(6):627-35
pubmed: 18958493
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
Semin Cancer Biol. 2020 Aug;64:93-101
pubmed: 31330185
Chest. 2009 Sep;136(3):888-896
pubmed: 19736192
Lung Cancer. 2005 Jul;49 Suppl 1:S99-S103
pubmed: 15950812
J Pathol. 2002 Jul;197(3):363-71
pubmed: 12115883
Ann Oncol. 2014 Jun;25(6):1184-92
pubmed: 24669013
Clin Cancer Res. 2004 Feb 1;10(3):849-59
pubmed: 14871960
Nat Genet. 2011 Aug 28;43(10):1022-5
pubmed: 21874000
Transl Lung Cancer Res. 2018 Oct;7(5):537-542
pubmed: 30450291
J Pathol. 2015 Oct;237(2):203-14
pubmed: 26011651
Cancer Res. 2016 Jan 15;76(2):319-28
pubmed: 26554828
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9008-9013
pubmed: 30975761
Clin Cancer Res. 2014 Mar 1;20(5):1323-34
pubmed: 24443521
Lung Cancer. 2007 Nov;58(2):220-30
pubmed: 17659810
Arch Toxicol. 2018 May;92(5):1785-1795
pubmed: 29523930
Genes Chromosomes Cancer. 2009 Jul;48(7):615-23
pubmed: 19396864
J Thorac Oncol. 2018 May;13(5):606-623
pubmed: 29524617
J Natl Cancer Inst. 2009 May 6;101(9):678-86
pubmed: 19401544
Bioinformatics. 2009 Nov 15;25(22):2906-12
pubmed: 19759197
J Toxicol Environ Health B Crit Rev. 2011;14(1-4):179-245
pubmed: 21534089
Lung Cancer. 2018 Dec;126:15-24
pubmed: 30527180
Expert Opin Biol Ther. 2019 Jul;19(7):697-706
pubmed: 31046484
Lung Cancer. 2018 Oct;124:95-101
pubmed: 30268487
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Oncotarget. 2017 Jan 10;8(2):2758-2770
pubmed: 27835874
J Natl Cancer Inst. 2018 Dec 1;110(12):1328-1341
pubmed: 30517737
Arch Pathol Lab Med. 2018 Jun;142(6):753-760
pubmed: 29480760
Mod Pathol. 2015 Aug;28(8):1043-57
pubmed: 26022455
J Thorac Oncol. 2016 Nov;11(11):2006-2017
pubmed: 27422796
Ann Transl Med. 2017 Jun;5(11):244
pubmed: 28706912
Nature. 2017 Jun 22;546(7659):549-553
pubmed: 28614305
Cancer Res. 2015 Jan 15;75(2):264-9
pubmed: 25488749
Nat Genet. 2011 Jun 05;43(7):668-72
pubmed: 21642991
Cancer Treat Rev. 2011 Nov;37(7):543-58
pubmed: 21288646
Cancer Immunol Immunother. 2016 Aug;65(8):909-17
pubmed: 27207606
J Thorac Oncol. 2018 Jan;13(1):124-133
pubmed: 29079455
Cancer Discov. 2018 Dec;8(12):1548-1565
pubmed: 30322867
Am J Ind Med. 2019 Jun;62(6):471-477
pubmed: 31087402
Free Radic Biol Med. 2018 Feb 1;115:266-277
pubmed: 29229551
Arch Pathol Lab Med. 2012 Mar;136(3):277-93
pubmed: 22372904
Cancer Res. 2009 Dec 1;69(23):9073-82
pubmed: 19887624
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
Front Oncol. 2020 Feb 07;10:105
pubmed: 32117755
Lab Invest. 2004 Aug;84(8):1013-23
pubmed: 15122306
J Cell Physiol. 2012 Jan;227(1):44-58
pubmed: 21412769
High Throughput. 2018 Jul 27;7(3):
pubmed: 30060501
Thorax. 1999 Jul;54(7):638-52
pubmed: 10377212
Clin Cancer Res. 2003 Aug 1;9(8):3080-97
pubmed: 12912960
J Toxicol Environ Health A. 2018;81(5):98-105
pubmed: 29265930
Front Oncol. 2019 Nov 29;9:1293
pubmed: 31850200
Int J Mol Sci. 2018 May 30;19(6):
pubmed: 29848954
Dis Markers. 2017;2017:1310478
pubmed: 29085180
J Clin Oncol. 2018 Oct 1;36(28):2863-2871
pubmed: 30113886
Cancer Res. 2002 Sep 1;62(17):4963-7
pubmed: 12208747
J Thorac Oncol. 2017 Aug;12(8):1309-1319
pubmed: 28389374

Auteurs

Benjamin Wadowski (B)

Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

Assunta De Rienzo (A)

Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

Raphael Bueno (R)

Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: rbueno@bwh.harvard.edu.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Produits chimiques inorganiques › Composés du silicium › Silice › Acide silicique › Silicates › Amiante › The Molecular Basis of Malignant Pleural Mesothelioma.
questionsmedicales.fr › Sciences de l'information › Informatique › Biologie informatique › The Molecular Basis of Malignant Pleural Mesothelioma.
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › The Molecular Basis of Malignant Pleural Mesothelioma.
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › The Molecular Basis of Malignant Pleural Mesothelioma.
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › The Molecular Basis of Malignant Pleural Mesothelioma.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Molecular Basis of Malignant Pleural Mesothelioma.
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs de la plèvre › Mésothéliome malin › The Molecular Basis of Malignant Pleural Mesothelioma.
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs de la plèvre › The Molecular Basis of Malignant Pleural Mesothelioma.
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Transcriptome › The Molecular Basis of Malignant Pleural Mesothelioma.